{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:42:10Z","timestamp":1790221330143,"version":"4.1.0"},"update-to":[{"DOI":"10.1016\/j.bulcan.2021.01.007","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"record-id":"49678"},{"DOI":"10.1016\/j.bulcan.2021.01.007","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000}}],"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bulcan.2021.01.007","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T17:09:34Z","timestamp":1617383374000},"page":"544-552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["WITHDRAWN: Patients sous palbociclib et hormonoth\u00e9rapie pour un cancer du sein m\u00e9tastatique\u00a0: peut-on pr\u00e9dire la survenue d\u2019une h\u00e9matotoxicit\u00e9 pr\u00e9coce et s\u00e9v\u00e8re\u00a0?"],"prefix":"10.1016","volume":"108","author":[{"given":"L\u00e9a","family":"Vazquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Debourdeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.01.007_bib0140","unstructured":"International Agency for. Research on cancer. (page consult\u00e9e le 19 juin 2019). World Health Organization: global cancer data. En ligne. https:\/\/www.who.int\/cancer\/PRGlobocanFinal.pdf."},{"key":"10.1016\/j.bulcan.2021.01.007_bib0145","unstructured":"Institut National du Cancer. (page consut\u00e9e le 19juin 2019. Les cancers en France. En ligne: https:\/\/www.e-cancer.fr\/ressources\/cancers_en_france."},{"key":"10.1016\/j.bulcan.2021.01.007_bib0150","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NC ; Breast Cancer Version 1). NCCN; 2019. [cit\u00e9 19 juin 2019. Disponible sur : https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"issue":"10","key":"10.1016\/j.bulcan.2021.01.007_bib0155","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"25","author":"Cardoso","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2021.01.007_bib0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13058-015-0542-y","article-title":"Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA","volume":"17","author":"Hayes","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.bulcan.2021.01.007_bib0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12282-017-0818-4","article-title":"Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4\u00a0and 6\u00a0inhibitors: a systematic review and meta-analysis","volume":"25","author":"Kassem","year":"2018","journal-title":"Breast Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2021.01.007_bib0170","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/cam4.1970","article-title":"Safety and efficacy profile of cyclin-dependent kinases 4\/6\u00a0inhibitor palbociclib in cancer therapy: a meta-analysis of clinical trials","volume":"8","author":"Guo","year":"2019","journal-title":"Cancer Med"},{"issue":"20","key":"10.1016\/j.bulcan.2021.01.007_bib0175","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.01.007_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2017.05.016","article-title":"Meta-analysis of selected toxicity endpoints of CDK4\/6\u00a0inhibitors: palbociclib and ribociclib","volume":"35","author":"Costa","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.bulcan.2021.01.007_bib0185","unstructured":"Food and Drug Administration (page consult\u00e9 le 19juin2019. Palbociclib full prescribing informations. En ligne:. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207103s000lbl.pdf."},{"issue":"10","key":"10.1016\/j.bulcan.2021.01.007_bib0190","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in combination with fulvestrant in women with hormone receptor-positive\/HER2\u2212negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase IIIstudy (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bulcan.2021.01.007_bib0195","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10147-018-1353-9","article-title":"Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2\u00a0subgroup analysis of Japanese patients","volume":"24","author":"Mukai","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2021.01.007_bib0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/djy109","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+\/HER2\u2212 advanced breast cancer","volume":"111","author":"Di\u00e9ras","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2021.01.007_bib0205","series-title":"CTCAE version 4. 03","year":"2010"},{"issue":"1","key":"10.1016\/j.bulcan.2021.01.007_bib0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6\u00a0inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2\u2212negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2\u00a0study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2021.01.007_bib0215","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2021.01.007_bib0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bulcan.2021.01.007_bib0225","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/2042098617722516","article-title":"Gastrointestinal adverse effects of cyclin-dependent kinase 4\u00a0and 6\u00a0inhibitors in breast cancer patients: a systematic review and meta-analysis","volume":"8","author":"Shohdy","year":"2017","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"10.1016\/j.bulcan.2021.01.007_bib0230","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-019-05176-1","article-title":"Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy","volume":"176","author":"Varella","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.bulcan.2021.01.007_bib0235","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamaoncol.2015.3113","article-title":"JAMA oncology patient page. Performance status in patients with cancer","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2021.01.007_bib0240","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0301-472X(02)00802-0","article-title":"Hematologic consequences of exposure to ionizing radiation","volume":"30","author":"Dainiak","year":"2002","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.bulcan.2021.01.007_bib0245","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/1097-0142(197309)32:3<699::AID-CNCR2820320324>3.0.CO;2-V","article-title":"Bone marrow regeneration and extension after extended field irradiation in Hodgkin's disease","volume":"32","author":"Rubin","year":"1973","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2021.01.007_bib0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12094-016-1504-2","article-title":"Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer","volume":"19","author":"Franco","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2021.01.007_bib0255","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.prro.2017.03.008","article-title":"Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation","volume":"7","author":"Rose","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2021.01.007_bib0260","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.bjc.6601231","article-title":"Performance status score: do patients and their oncologists agree?","volume":"89","author":"Blagden","year":"2003","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2021.01.007_bib0265","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.1996.14.2.636","article-title":"Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia","volume":"14","author":"Blay","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.01.007_bib0135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis","volume":"19","author":"Ethier","year":"2017","journal-title":"Breast Cancer Res"}],"updated-by":[{"DOI":"10.1016\/j.bulcan.2021.01.007","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"record-id":"49678"},{"DOI":"10.1016\/j.bulcan.2021.01.007","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000}},{"DOI":"10.1016\/j.bulcan.2023.11.009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000}}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:20:02Z","timestamp":1762104002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121001028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0007455121001028"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.01.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: Patients sous palbociclib et hormonoth\u00e9rapie pour un cancer du sein m\u00e9tastatique\u00a0: peut-on pr\u00e9dire la survenue d\u2019une h\u00e9matotoxicit\u00e9 pr\u00e9coce et s\u00e9v\u00e8re\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}